A monoclonal antibody raised against an undecapeptide sequence from human transforming growth factor alpha recognizes

K A Ellem1, M S Wilson, C Fardoulys

  • 1Queensland Institute of Medical Research, Bramston Terrace, Brisbane, Australia.

Insights

A novel monoclonal antibody targets a specific epitope on human transforming growth factor alpha. This antibody unexpectedly binds to centrosomes, identifying a new protein involved in mitotic spindle organization.

Area of Science:

  • Cell Biology
  • Immunology
  • Molecular Biology

Background:

  • Monoclonal antibody (mAbIIa138) was generated against a peptide from human transforming growth factor alpha (TGF-α).
  • The antibody targets a hexapeptide epitope (RFLVQE) within the [22-27] residue range of TGF-α.
  • TGF-α plays a role in cell receptor binding.

Purpose of the Study:

  • To characterize the binding specificity of mAbIIa138.
  • To investigate the potential of mAbIIa138 as a cellular marker.
  • To identify novel centrosomal proteins involved in cell division.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) to test antibody reactivity with native and reduced TGF-α.
  • Immunostaining of mammalian cells to determine antibody binding sites.
  • Analysis of epitope antigenic stringency using amino acid replacement sets.
  • Bioinformatic searches for homologous proteins.

Main Results:

  • mAbIIa138 did not react with native or reduced TGF-α, suggesting conformational interference.
  • The antibody specifically bound to centrosomes in late-interphase and mitotic cells.
  • Centrosome staining intensity correlated with mitotic spindle organization activity.
  • The epitope demonstrated high tolerance to single amino acid substitutions (25 replacements).

Conclusions:

  • mAbIIa138 recognizes an epitope on a novel centrosomal protein, designated CSP alpha.
  • CSP alpha is involved in mitotic spindle organization or function.
  • CSP alpha is an unsequenced protein, specific to the centrosome.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...